“…Although both bind to the same intracellular immunophilin, termed 12-kDa FK506-binding protein (FKBP12), the sirolimus-FKBP12 complex interacts with a distinct molecular target, known as mammalian target of rapamycin (mTOR), which results in the inhibition of multiple biochemical pathways critical for cytokine/growth factor-induced cellular proliferation, ribosome synthesis, translation initiation, and cell cycle progression into S phase (46) . Although sirolimus was shown recently to inhibit DC migration and DC-mediated T-cell activation (48) , our results indicated that sirolimus did not modify the levels of iNOS protein (Figure 3, lane 5, and Figure 5E) and NO production ( Figure 2) elicited by nickel sulfate.…”